The global contract development and manufacturing organization (CDMO) sector continues its aggressive expansion as two of the industry's largest players announced significant capacity investments this week. Lonza has broken ground on a new spray-drying facility in Bend, Oregon, while Samsung Biologics has secured a $262 million manufacturing contract, underscoring the persistent demand for outsourced pharmaceutical production capacity across both small-molecule and biologics platforms.

Lonza's new Oregon facility represents a strategic bet on spray-drying technology, which has become increasingly critical for enhancing the bioavailability of poorly soluble drug compounds. The Bend site will complement Lonza's existing spray-drying operations in Europe, providing North American clients with local access to a technology that has seen demand surge alongside the industry's growing pipeline of BCS Class II and IV compounds. Spray-drying dispersions (SDD) can improve oral bioavailability by orders of magnitude for compounds that would otherwise fail in development due to solubility limitations, making the technology a bottleneck for many advanced drug candidates.

The investment reflects a broader trend of CDMO capacity reshoring that has accelerated since the pandemic exposed vulnerabilities in globally distributed pharmaceutical supply chains. United States-based drug sponsors increasingly prefer domestic or near-shore manufacturing partners to reduce lead times, simplify regulatory oversight, and mitigate geopolitical risks. Lonza's decision to build in Oregon, rather than expanding existing European sites, signals confidence in the long-term demand trajectory from North American biotech and pharmaceutical clients who value proximity to their development teams.

For API and intermediate suppliers, Lonza's expansion creates both opportunities and competitive dynamics. A new spray-drying facility will require upstream supply of formulated intermediates, excipients, and processed APIs optimized for SDD processing. Suppliers with expertise in particle engineering and amorphous solid dispersion feedstocks may find new partnership opportunities as Lonza scales its Bend operations. However, the concentration of advanced manufacturing capabilities within large CDMOs also raises barriers for smaller contract manufacturers who lack equivalent spray-drying infrastructure.

Samsung Biologics' $262 million contract win, meanwhile, reinforces the South Korean CDMO's dominance in large-molecule manufacturing. The deal, whose sponsor was not disclosed, adds to Samsung's already massive order backlog at its Songdo complex, where the company operates some of the world's largest single-site biomanufacturing capacity. Samsung has consistently invested ahead of demand, adding new plants before existing ones reach full utilization, a strategy that has allowed it to offer rapid capacity deployment that smaller CDMOs cannot match.

The Samsung contract also highlights the continued strength of the biologics outsourcing market despite concerns about biosimilar competition and pricing pressure. While small-molecule CDMOs face margin compression from commoditized capacity, biologics CDMOs benefit from higher technical barriers, longer customer relationships, and the complexity of switching manufacturing partners for approved biological products. This structural advantage has allowed Samsung and peers like Lonza and WuXi Biologics to maintain premium pricing even as overall biotech funding has fluctuated.

The parallel moves by Lonza and Samsung reflect a CDMO industry that is consolidating around scale and specialization. Mid-tier CDMOs are increasingly squeezed between large players who can offer integrated end-to-end services and niche specialists who dominate specific technologies like antibody-drug conjugates or viral vector production. For pharmaceutical companies evaluating manufacturing partners, the choice increasingly comes down to whether their project requires broad platform capabilities or deep expertise in a particular modality.

For API suppliers serving the CDMO channel, these expansion announcements signal sustained demand growth through at least 2028. Both Lonza's spray-drying investment and Samsung's contract represent multi-year capacity commitments that will require ongoing procurement of raw materials, intermediates, and starting materials. Suppliers who can demonstrate consistent quality, regulatory compliance, and reliable supply chains will be best positioned to capture business from these expanding manufacturing networks.

The Boston Scientific cybersecurity incident also referenced alongside these CDMO announcements serves as a reminder that supply chain resilience extends beyond manufacturing capacity. Digital infrastructure vulnerabilities can disrupt production schedules and delivery timelines, creating cascading effects throughout pharmaceutical supply networks. CDMOs and their suppliers are increasingly investing in cybersecurity as a core operational competency, recognizing that data integrity and system availability are as critical to delivery performance as physical production capability.

Looking ahead, the CDMO sector's expansion trajectory shows no signs of slowing. The combination of growing biologics pipelines, increasing complexity of drug molecules requiring specialized formulation technologies, and the ongoing shift toward outsourcing among both large pharma and emerging biotech companies creates a favorable demand environment. For suppliers across the pharmaceutical value chain, aligning with the capacity expansion strategies of leading CDMOs like Lonza and Samsung Biologics represents a compelling growth opportunity in an otherwise challenging market landscape.